Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27140032 | 1.00 | JAK2 (0.41) | JAK2JAK1BCHEL3MBTL1ABCB1 | |
| SCHEMBL27154353 | 0.88 | BCHE (0.41) | BCHETMEM97SIGMAR1 | |
| SCHEMBL20132907 | 0.86 | PRMT5 (0.45) | JAK2JAK1BCHEL3MBTL1ABCB1 | |
| SCHEMBL27097940 | 0.85 | NR1H2 (0.39) | PRMT5WDR77GPR119 | |
| SCHEMBL28959331 | 0.84 | L3MBTL1 (0.50) | JAK2JAK1L3MBTL1PRMT5WDR77 | |
| SCHEMBL29547819 | 0.83 | NR1H2 (0.41) | JAK2JAK1PRMT5WDR77GPR119 | |
| SCHEMBL22906879 | 0.83 | NR1H2 (0.41) | JAK2JAK1PRMT5WDR77GPR119 | |
| SCHEMBL22906672 | 0.82 | L3MBTL1 (0.51) | JAK2JAK1L3MBTL1PRMT5WDR77 | |
| SCHEMBL20129209 | 0.81 | L3MBTL1 (0.47) | JAK2JAK1L3MBTL1PRMT5WDR77 | |
| SCHEMBL20132906 | 0.81 | L3MBTL1 (0.47) | JAK2JAK1L3MBTL1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | JAK2 2782/4885JAK1 3234/4885BCHE 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.